Document is current
Any future updates will be listed below
-
Authors
Øyri, Linn K. L.
Christensen, Jacob J.
Sebert, Sylvain
Thoresen, Magne
Michelsen, Trond M.
Ulven, Stine M.
Brekke, Hilde K.
Retterstøl, Kjetil
Brantsæter, Anne Lise
Magnus, Per
Bogsrud, Martin P.
Holven, Kirsten B.
-
Funding
Funding for this research was provided by:
the Throne Holst Foundation for Nutrition Research
Nasjonalforeningen for Folkehelsen
Eckbos Legate
the Freia Corporation Medical Fund
the Blix Foundation for the Promotion of Medical Research
Medisinske fakultet, Universitetet i Oslo
- License Information
-
More Information
Article History
Received: 6 October 2022
Accepted: 18 January 2023
First Online: 6 February 2023
Declarations
:
: The establishment of MoBa and initial data collection were based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics. MoBa is currently regulated by the Norwegian Health Registry Act. The participants volunteered and gave written informed consent. The current study was approved by The Regional Committees for Medical and Health Research Ethics (no. 2017/1285 and 2017/1286).
: Not applicable.
: During the past 5 years, JJC reports grants or personal fees from Mills DA and Amgen, none of which are related to the content of this manuscript. SMU has received research grants Tine DA, and Olympic Seafood, none of which are related to the content of this manuscript. KR personal fees from Amgen, personal fees from Mills AS, personal fees from The Norwegian Medical Association, personal fees from The Norwegian Directorate of Health, personal fees from Sanofi, personal fees from Takeda, personal fees from Chiesi, personal fees from Bayer, and personal fees from MSD, none of which are related to the content of this manuscript. MPB reports grants and personal fees from Amgen, grants and personal fees from Sanofi, none of which are related to the content of this manuscript. KBH has received research grants or honoraria from Mills AS, Amgen, and Sanofi, none of which are related to the content of this manuscript. LKLØ, SS, MT, TMM, HKB, ALB, and PM declare that they have no competing interests.
